MARK2 and metastatic melanoma: Comparably, the FDA approved ipilimumab for metastatic melanoma [86] and, in addition, vemurafenib (Zelboraf, Roche), a BRAF serine-threonine kinase inhibitor [87], and peginterferon alfa-2b (Sylatron) for the therapy of melanoma [88] (Table 3).